Shockwave Medica has announced clearance from the US Food and Drug Administration (FDA) of the Lithoplasty system for the treatment of calcified plaque in patients with peripheral arterial disease.
According to Shockwave Medical, the Lithoplasty system is the first-ever device designed to selectively target hardened calcium in patients with cardiovascular disease. The device integrates two familiar and powerful technologies: the calcium-disrupting power of sound waves (known as “lithotripsy”, which is commonly used to treat patients with kidney stones) with the simplicity of angioplasty balloon catheter devices. Intermittent lithotripsy pulses disrupt both superficial and deep vascular calcium, while minimising soft tissue injury, and an integrated angioplasty balloon expands blockages at low pressures to restore blood flow.
“Lithoplasty represents a new mechanism of treatment and is revolutionary for the care of patients with calcified peripheral vascular disease, a difficult-to-treat patient population,” said Kenneth Rosenfield, section head for Vascular Medicine and Intervention at Massachusetts General Hospital, Boston, USA. “Existing devices for treating these patients have significant shortcomings that make it challenging to successfully open arteries, while minimising vascular injury and complications. Lithoplasty is a unique approach that allows us to successfully treat these diseased vessels using a device built on a familiar balloon catheter platform, while minimising the risk of vessel injury, including dissections that require stenting or other additional interventions.”
“This marks an exciting milestone for the company as we prepare to begin our commercial activities in the United States,” said Shockwave Medical CEO and co-founder Daniel Hawkins. “We view this as an important validation of our technology’s potential to address the burdens of vascular calcification, and we are looking forward to working with the clinical community to deeply integrate Lithoplasty into the care pathway to improve outcomes for patients with advanced cardiovascular diseases.”
Positive data from the DISRUPT PAD study, a single-arm, two-phase, multicentre study evaluating the safety and performance of the Shockwave Medical Lithoplasty system to treat peripheral artery disease, supported the clearance. Clinical data from DISRUPT PAD demonstrated compelling safety, consistent procedural success across all patient subgroups, significant and immediate increases in blood flow in treated vessels, and minimal vessel injury. The latest clinical results from the DISRUPT PAD studies will be presented at the Vascular Interventional Advances (VIVA) conference on 19 September 2016 in Las Vegas, USA.
“We are thrilled to reach this important milestone and we look forward to partnering with physicians to help advance the treatment of peripheral artery disease,” said Todd Brinton, clinical associate professor of Medicine at Stanford and co-founder of Shockwave Medical.
The company plans a limited US commercial release of the Lithoplasty system in 2017 and will initiate a global randomised trial to gather further clinical data on the benefits of Lithoplasty treatment.